

CITATION REPORT

List of articles citing

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

DOI: 10.1016/0304-3940(92)90444-c
Neuroscience Letters, 1992, 135, 235-8.

Source: <https://exaly.com/paper-pdf/23176425/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
754	Biochemistry of Alzheimer's disease amyloid plaques. 1993 , 26, 339-49		32
753	Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. 1993 , 34, 631-3		57
752	Localization of sulfated glycoprotein-2/clusterin mRNA in the rat brain by in situ hybridization. 1993 , 334, 209-27		73
751	News & Views. 1993 , 16, 136-149		1
750	Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. 1993 , 261, 921-3		7110
749	Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. 1993 , 16, 403-9		384
748	Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. 1993 , 11, 575-80		940
747	Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. 1993 , 43, 1467-72		3228
746	Apolipoprotein E polymorphism and Alzheimer's disease. 1993 , 342, 697-9		1124
745	Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. 1993 , 342, 710-1		478
744	Binding of IgG to amyloid beta A4 peptide via the heavy-chain hinge region with preservation of antigen binding. 1993 , 48, 199-203		7
743	Sequestration of amyloid beta-peptide. 1993 , 695, 139-43		24
742	Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. 1993 , 90, 1977-81		3441
741	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. 1993 , 90, 9649-53		1288
740	Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. 1993 , 90, 11282-6		1185
739	Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. 1993 , 90, 8098-102		1176
738	The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. <i>Biochemical Journal</i> , 1993 , 293 (Pt 1), 27-30	3.8	274

737	Genetics of Alzheimer's disease. Some molecular understanding of a diverse phenotype. 1994 , 164, 153-6	3
736	Alzheimer's Disease: Clinical Molecular Genetics. 1994 , 10, 239-247	14
735	Processing of Alzheimer A beta-amyloid precursor protein: cell biology, regulation, and role in Alzheimer disease. 1994 , 36, 29-50	42
734	Alzheimer's disease and possible gene interaction. 1994 , 263, 537	103
733	A potential noninvasive neurobiological test for Alzheimer's disease. 1994 , 266, 1051-4	174
732	Immunoreactivity patterns in neurofibrillary tangles of the inferior temporal cortex in Alzheimer disease. 1994 , 22, 105-22	7
731	Beta-amyloid formation by myocytes of leptomeningeal vessels. 1994 , 87, 233-41	135
730	Rosenthal fibers, eosinophilic inclusions, and anchorage densities with desmosome-like structures in astrocytes in Alzheimer's disease. 1994 , 87, 355-61	9
729	Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. 1994 , 88, 413-9	66
728	Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. 1994 , 87, 469-80	248
727	Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. 1994 , 4, 178-94	111
726	Alzheimer's disease: Recent advances in molecular pathology and genetics. 1994 , 9, 431-444	7
725	Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. 1994 , 54, 199-205	76
724	Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease. 1994 , 35, 432-8	25
723	Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. 1994 , 36, 889-95	119
722	APOE is a major susceptibility gene for Alzheimer's disease. 1994 , 5, 663-7	82
721	Unifying features of systemic and cerebral amyloidosis. 1994 , 8, 49-64	59
720	ApoE-epsilon 4 and early-onset Alzheimer's. 1994 , 7, 10-1	133

719	Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. 1994 , 7, 74-8	413
718	Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. 1994 , 372, 92-4	835
717	Proteoglycans, glycosaminoglycans and amyloid deposition. 1994 , 8, 575-97	6
716	Alzheimer's disease. The apolipoprotein E connection. 1994 , 4, 362-5	34
715	Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. 1994 , 76, 300-3	29
714	Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques. 1994 , 15, 621-7	49
713	Alzheimer's disease and soluble A beta. 1994 , 15, 143-52	112
712	APP processing, A beta-amyloidogenesis, and the pathogenesis of Alzheimer's disease. 1994 , 15, 253-6	37
711	Studying the Alzheimer's disease brain: insights, puzzles, and opportunities. 1994 , 15 Suppl 2, S79-83	5
710	Chaperoning Alzheimer's amyloids. 1994 , 15 Suppl 2, S97-9	6
709	Genes in early onset Alzheimer's disease: implications for AD research. 1994 , 15 Suppl 2, S149-53	4
708	Apolipoprotein E: structure-function relationships. 1994 , 45, 249-302	604
707	Complex genetic disease: can genetic strategies in Alzheimer's disease and new genetic mechanisms be applied to epilepsy?. 1994 , 35 Suppl 1, S20-8	4
706	The multiligand alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP). Binding and endocytosis of fluid phase and membrane-associated ligands. 1994 , 737, 20-38	50
705	Alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Relationship to apolipoprotein E and role in Alzheimer disease senile plaques. 1994 , 737, 88-95	12
704	Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. 1994 , 4, 507-515	53
703	Identification of glutamine and lysine residues in Alzheimer amyloid beta A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to alpha 2M receptor. 1994 , 338, 161-6	54
702	Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. 1994 , 17, 525-30	576

701	A hypothesis on the aetiology of Alzheimer's disease: description of a model involving a misfolded chaperone. 1994 , 43, 372-80		7
700	Apolipoprotein E and Alzheimer's disease. 1994 , 4, 703-7		33
699	Apolipoprotein E expression in the cerebellum of normal and hypercholesterolemic rabbits. 1994 , 21, 115-23		7
698	Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. <i>Neuroscience Letters</i> , 1994 , 178, 221-4	3-3	73
697	Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. <i>Neuroscience Letters</i> , 1994 , 182, 55-8	3-3	76
696	Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. <i>Neuroscience Letters</i> , 1994 , 167, 73-6	3-3	43
695	Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. <i>Neuroscience Letters</i> , 1994 , 175, 46-8	3-3	106
694	Lack of association between apolipoprotein E allele epsilon 4 and sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 1994 , 169, 175-8	3-3	53
693	Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. 1994 , 94, 860-9		302
692	Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. 1994 , 91, 9382-6		143
691	Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. 1994 , 91, 11183-6		421
690	Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. 1994 , 14, 7221-33		111
689	Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. 1995 , 92, 4299-303		336
688	Apolipoprotein E and Alzheimer disease. 1995 , 92, 4725-7		414
687	Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. 1995 , 92, 763-7		322
686	Genetic dissection of Alzheimer disease, a heterogeneous disorder. 1995 , 92, 8552-9		157
685	Expression of human beta-amyloid peptide in transgenic <i>Caenorhabditis elegans</i> . 1995 , 92, 9368-72		501
684	The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. 1995 , 270, 3063-7		265

683	A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. 1995,		
682	Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. <i>Biochemical Journal</i> , 1995 , 306 (Pt 2), 599-604	3.8	225
681	The toxicity in vitro of beta-amyloid protein. <i>Biochemical Journal</i> , 1995 , 311 (Pt 1), 1-16	3.8	430
680	Human Nervous System. 1995 , 325-344		3
679	Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. 1995 , 17, 242-8		137
678	Identification and expression analysis of a potential familial Alzheimer disease gene on chromosome 1 related to AD3. 1995 , 92, 12180-4		53
677	Genetic susceptibility to Alzheimer disease. 1995 , 11, 504-8		109
676	Molecular biology and genetics of Alzheimer's disease. 1995 , 2, 465-76		2
675	Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. 1995 , 60, 456-60		31
674	Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. 1995 , 37, 211-7		276
673	Apolipoprotein E genotypes in Parkinson's disease with and without dementia. 1995 , 37, 242-5		59
672	A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing. 1995 , 38, 225-30		49
671	Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. 1995 , 38, 460-3		67
670	Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions. 1995 , 352, 92-105		27
669	Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions. 1995 , 90, 608-14		11
668	Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14-linked early onset Alzheimer's disease. 1995 , 90, 257-65		20
667	In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. 1995 , 41, 570-4		40
666	Complete cerebral ischemia with short-term survival in rat induced by cardiac arrest. II. Extracellular and intracellular accumulation of apolipoproteins E and J in the brain. 1995 , 674, 341-6		75

665	Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. 1995 , 685, 154-62		19
664	Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. 1995 , 685, 211-6		65
663	Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. 1995 , 691, 235-8		49
662	Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. 1995 , 698, 217-22		64
661	Amyloid Formation in Response to [Cell Stress Occurs In Vitro, but Not In Vivo, in Islets of Transgenic Mice Expressing Human Islet Amyloid Polypeptide. <i>Molecular Medicine</i> , 1995 , 1, 542-553	6.2	33
660	Alzheimer's disease—New approaches to old problems. 1995 , 7, 419-435		1
659	Apolipoprotein E genotypes in AA and AL amyloidoses. 1995 , 2, 159-162		7
658	Brief Report: Apolipoprotein E ε4 allele does not correlate with amyloid plaques in transmissible spongiform encephalopathies. 1995 , 2, 36-38		1
657	Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). 1995 , 92, 3586-90		189
656	Characterization of apolipoprotein J-Alzheimer's A beta interaction. 1995 , 270, 7563-7		157
655	Apolipoprotein E: a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease. 1995 , 25, 223-9		48
654	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. 1995 , 7, 361-383		2
653	Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. 1995 , 270, 9564-70		306
652	Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. 1995 , 270, 9039-42		150
651	Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. 1995 , 52, 373-8		123
650	GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. 1995 , 6, 221-58		14
649	Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. 1995 , 32, 642-4		33
648	Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. 1995 , 270, 17610-5		47

647	Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. 1995 , 15, 219-28		181
646	Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. 1995 , 14, 447-56		157
645	Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. 1995 , 4, 291-7		58
644	Lipids and atherosclerosis. 1995 , 16, 509-710		10
643	Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system. 1995 , 33, 37-46		36
642	Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. <i>Neuroscience Letters</i> , 1995 , 201, 49-52	3-3	57
641	Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. <i>Neuroscience Letters</i> , 1995 , 191, 79-82	3-3	97
640	Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. <i>Neuroscience Letters</i> , 1995 , 193, 105-8	3-3	43
639	ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. <i>Neuroscience Letters</i> , 1995 , 195, 5-8	3-3	102
638	The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. <i>Neuroscience Letters</i> , 1995 , 196, 105-8	3-3	21
637	Phosphorylation of tau in apolipoprotein E-deficient mice. <i>Neuroscience Letters</i> , 1995 , 199, 5-8	3-3	58
636	Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. <i>Neuroscience Letters</i> , 1995 , 199, 95-8	3-3	29
635	Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. <i>Neuroscience Letters</i> , 1995 , 202, 101-4	3-3	60
634	The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. 1995 , 26, 254-7		78
633	Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. 1995 , 34, 11142-51		56
632	Identification of a unique apolipoprotein E allele in <i>Microcebus murinus</i> ; ApoE brain distribution and co-localization with beta-amyloid and tau proteins. 1995 , 2, 169-76		16
631	A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. 1995 , 4, 433-42		54
630	Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to Tau and PHF in Alzheimer's disease. 1995 , 132, 162-71		45

629	Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. 1995 , 371, 110-4		41
628	Familial cerebral amyloid angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. 1995 , 129, 74-5		30
627	Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. 1995 , 134, 146-9		21
626	Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. 1995 , 16, 505-13		55
625	Mutant and native human beta-amyloid precursor proteins in transgenic mouse brain. 1995 , 16, 685-99		42
624	Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. 1995 , 333, 1242-7		412
623	Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. <i>Neuroscience Letters</i> , 1995 , 186, 115-8	3-3	64
622	A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. <i>Neuroscience Letters</i> , 1995 , 187, 79-82	3-3	148
621	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. 1995 , 2, 163-166		7
620	The role of beta-amyloid in the development of Alzheimer's disease. 1995 , 7, 97-109		11
619	Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). 1995 , 2, 269-279		45
618	Is Alzheimer's disease an apolipoprotein E amyloidosis?. 1995 , 345, 956-8		146
617	Apolipoprotein E in Creutzfeldt-Jakob disease. 1995 , 345, 68-69		24
616	Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. 1995 , 90, 239-43		38
615	Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. 1995 , 67, 65-72		147
614	Allelic variation of apolipoprotein E in Japanese sporadic Creutzfeldt-Jakob disease patients. <i>Neuroscience Letters</i> , 1995 , 187, 209-11	3-3	19
613	Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis. <i>Neuroscience Letters</i> , 1995 , 183, 35-8	3-3	29
612	APOE alleles in Alzheimer's disease and vascular dementia in a population aged 85+. 1996 , 17, 373-6		26

611	Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism. 1996 , 17, 523-6	34
610	Beta AP deposition and head trauma. 1996 , 17, 415-9	21
609	Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. 1996 , 17, 773-80	98
608	Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. 1996 , 802, 42-9	8
607	NIA/AlzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. 1996 , 802, 177-224	
606	Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. 1996 , 777, 146-57	38
605	Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. 1996 , 777, 158-65	23
604	In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. 1996 , 35, 749-57	122
603	Seeding of A beta fibril formation is inhibited by all three isoforms of apolipoprotein E. 1996 , 35, 12623-8	109
602	Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. 1996 , 35, 7123-30	57
601	No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy. <i>Neuroscience Letters</i> , 1996 , 204, 209-11	3-3 8
600	Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. 1996 , 3, 16-32	459
599	Single-step purification of two functional human apolipoprotein E variants hyperexpressed in <i>Escherichia coli</i> . 1996 , 7, 407-14	11
598	The fibril forming region of the beta-amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. 1996 , 219, 962-7	6
597	Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. 1996 , 223, 592-7	115
596	Molecular genetics of Alzheimer's disease. 1996 , 165, 13-7	20
595	Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. 1996 , 16, 881-91	924
594	Mechanisms of neuronal degeneration in Alzheimer's disease. 1996 , 16, 921-32	897

593	Scrapie in mice deficient in apolipoprotein E or glial fibrillary acidic protein. 1996 , 47, 449-53		45
592	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. 1996 , 11, 1708-1711		3
591	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. 1996 , 11, 1708-1711		5
590	Alzheimer's syndrome, not Alzheimer's disease. 1996 , 44, 96-7		3
589	Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (<i>Macaca fascicularis</i>). 1996 , 45, 199-203		4
588	Quantitation of apolipoprotein E. 1996 , 263, 170-87		9
587	Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. 1996 , 7, 273-8		15
586	Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. <i>Biochemical Journal</i> , 1996 , 313 (Pt 2), 575-80	3.8	61
585	The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. <i>Biochemical Journal</i> , 1996 , 314 (Pt 2), 701-7	3.8	110
584	Apolipoprotein J and Alzheimer's amyloid beta solubility. <i>Biochemical Journal</i> , 1996 , 316 (Pt 2), 671-9	3.8	165
583	Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. 1996 , 46, 413-9		133
582	Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. 1996 , 722, 71-7		37
581	Early-onset dementias: clinical, neuropathological and genetic characteristics. 1996 , 91, 451-65		19
580	Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. 1996 , 92, 180-5		23
579	Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. 1996 , 103, 1205-10		33
578	Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. 1996 , 103, 603-18		154
577	Biochemical and cognitive studies of apolipoprotein-E-deficient mice. 1996 , 28, 97-103		34
576	A beta A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 237, 6-15		30

575	Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. 1996 , 22, 334-41	36
574	Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II--A review of histopathological aspects. 1996 , 6, 115-20	88
573	The neurochemistry of Alzheimer's disease. 1996 , 168, 77-86	10
572	An ApoE-Abeta inhibition complex in Abeta fibril extension. 1996 , 3, 949-56	38
571	Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. 1996 , 39, 62-70	336
570	Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. 1996 , 40, 864-72	31
569	Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late-onset Swedish Alzheimer families. 1996 , 67, 306-11	19
568	Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. 1996 , 179, 443-7	50
567	Apolipoprotein E allele frequencies in sporadic inclusion body myositis. 1996 , 19, 1605-7	10
566	High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. 1996 , 39, 1728-32	22
565	Treatment Development Strategies for Alzheimer's Disease. 1996 , 2, 238-255	1
564	Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. 1996 , 14, 55-61	780
563	Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. 1996 , 8, 2652-61	35
562	β-Microglobulin amyloidosis. 1996 , 2, 373-386	4
561	SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. 1996 , 60, 644-9	92
560	The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. 1996 , 271, 10602-6	98
559	Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. 1996 , 60, 452-4	18
558	The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. 1996 , 61, 352-6	32

557	Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease. 1996 , 47, 1594-600		50
556	The A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 89-98		
555	The role of the Maillard reaction in other pathologies: Alzheimer's disease. 1996 , 11 Suppl 5, 7-12		33
554	A beta amyloidogenesis: unique, or variation on a systemic theme?. 1997 , 32, 361-404		69
553	Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. 1997 , 272, 21037-44		178
552	Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. 1997 , 54, 267-72		28
551	Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. <i>Biochemical Journal</i> , 1997 , 325 (Pt 1), 169-75	3.8	25
550	Domain stability in immunoglobulin light chain deposition disorders. 1997 , 50, 183-242		89
549	Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele. 1997 , 4, 13-17		10
548	Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. 1997 , 36, 10571-80		121
547	The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. 1997 , 145, 87-91		66
546	Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. 1997 , 36, 6243-50		103
545	Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. 1997 , 240, 715-20		60
544	Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. 1997 , 272, 348-61		244
543	Biology of A beta amyloid in Alzheimer's disease. 1997 , 4, 313-28		187
542	Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. 1997 , 42, 296-8		16
541	Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. 1997 , 25, 217-45		149
540	Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. 1997 , 44, 105-12		11

539	Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. <i>Neuroscience Letters</i> , 1997 , 221, 81-4	3-3	89
538	Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 231, 175-8	3-3	55
537	Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. <i>Neuroscience Letters</i> , 1997 , 239, 33-6	3-3	71
536	Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. <i>Neuroscience Letters</i> , 1997 , 224, 99-102	3-3	24
535	A cellular mechanism for the neuronal changes underlying Alzheimer's disease. 1997 , 78, 629-39		31
534	Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. 1997 , 17, 516-29		288
533	Apolipoprotein E4 and Alzheimer's disease in Sã Paulo-Brazil. 1997 , 55, 1-7		17
532	Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. 1997 , 23, 483-91		22
531	Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. 1997 , 389, 603-6		366
530	Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. 1997 , 243, 650-9		25
529	Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. 1997 , 750, 20-4		18
528	Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease. 1997 , 768, 208-14		24
527	Characterization of two highly amyloidogenic mutants of transthyretin. 1997 , 36, 5346-52		42
526	Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid A protein amyloidosis. 1997 , 85, 104-8		19
525	Immunohistochemical study of constituents other than beta-protein in canine senile plaques and cerebral amyloid angiopathy. 1997 , 93, 277-84		32
524	Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. 1997 , 94, 255-65		17
523	Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. 1997 , 173, 73-83		46
522	Association of human, rat, and rabbit apolipoprotein E with E-amyloid. 1997 , 49, 9-18		60

521	Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator. 1998 , 23, 369-76	11
520	Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. 1998 , 8, 735-57	20
519	Very early changes in olfactory functioning due to Alzheimer's disease and the role of apolipoprotein E in olfaction. 1998 , 855, 723-31	137
518	A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin. 1998 , 793, 47-53	17
517	Protein aggregation: folding aggregates, inclusion bodies and amyloid. 1998 , 3, R9-23	906
516	An immunohistochemical study of amyloid P component, apolipoprotein E and ubiquitin in human and murine amyloidoses. 1998 , 48, 362-7	9
515	Amyloid myopathy: an underdiagnosed entity. 1998 , 43, 719-28	59
514	Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. 1998 , 13, 767-74	10
513	Pick's disease: selective occurrence of apolipoprotein E-immunoreactive Pick bodies in the limbic system. 1998 , 95, 1-4	9
512	Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. 1998 , 291, 285-94	32
511	Apolipoprotein E is present in primary localized cutaneous amyloidosis. 1998 , 111, 417-21	19
510	The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. 1998 , 56, 541-69	179
509	Human apolipoprotein E allele-specific brain expressing transgenic mice. 1998 , 19, 407-13	30
508	Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. 1998 , 19, 517-25	60
507	Genetic association of apolipoprotein E with age-related macular degeneration. <i>American Journal of Human Genetics</i> , 1998 , 63, 200-6	11 357
506	Alzheimer's disease: genetic studies and transgenic models. 1998 , 32, 461-93	349
505	Ultrastructural evidence for the formation of amyloid fibrils within cardiomyocytes in isolated atrial amyloid. 1998 , 5, 35-42	16
504	Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. 1998 , 149, 79-86	44

503	Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. 1998 , 149, 175-82		51
502	Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. 1998 , 151, 314-25		102
501	Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. 1998 , 278, 183-94		121
500	Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. <i>American Journal of Pathology</i> , 1998 , 153, 1561-72	5.8	155
499	Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: A role for high-density lipoproteins?. 1998 , 28, 174-94		18
498	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. 1998 , 95, 15598-602		80
497	Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. 1998 , 64, 298-305		149
496	In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. 1998 , 5, 238-46		24
495	Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. 1998 , 27, 389-405		68
494	The prionoses and other conformational disorders. 1998 , 5, 212-24		37
493	Avian amyloidosis. 1998 , 27, 437-49		57
492	Molecular genetics of Alzheimer's disease. 1998 , 30, 560-5		111
491	APOE in non-Alzheimer amyloidoses: transmissible spongiform encephalopathies. 1998 , 51, 548-53		21
490	Alzheimer's Syndrome and not Alzheimer's disease: The historical struggle to define the disease. 1998 , 13, 92-95		1
489	Alzheimer disease. 1998 , 42, 1-54		166
488	ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. 1998 , 9, 3321-3		36
487	Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. 1998 , 18, 3261-72		196
486	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. 1998 , 3, d436-46		18

485	Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease. X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. 1998 , 9, 90-8	27
484	Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. 1998 , 18, 9335-41	138
483	Expression of human apolipoprotein E3 or E4 in the brains of Apoe ^{-/-} mice: isoform-specific effects on neurodegeneration. 1999 , 19, 4867-80	311
482	Structural characterization by computer experiments of the lipid-free LDL-receptor-binding domain of apolipoprotein E. 1999 , 12, 475-83	4
481	Genetic Predictors of Perioperative Neurologic and Neuropsychological Injury and Recovery. 1999 , 3, 34-46	5
480	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. 1999 , 56, 673-80	518
479	Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. 1999 , 96, 15233-8	408
478	What is the role of giant cells in AL-amyloidosis?. 1999 , 6, 89-97	27
477	Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. 1999 , 96, 3108-13	61
476	Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. 1999 , 72, 230-7	69
475	Mimicking lipid-binding-induced conformational changes in the human apolipoprotein E N-terminal receptor binding domain effects of low pH and propanol. 1999 , 264, 358-68	20
474	Is there a genetic basis for the deposition of beta-amyloid after fatal head injury?. 1999 , 19, 19-30	17
473	Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. 1999 , 56, 268-79	17
472	Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. 1999 , 77, 412-8	60
471	Moderate cortical EEG changes in apolipoprotein E-deficient mice during ageing and scopolamine treatment but not after nucleus basalis lesion. 1999 , 145, 386-92	2
470	Deposition of the prion protein (PrP) during the evolution of experimental Creutzfeldt-Jakob disease. 1999 , 98, 597-602	22
469	Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. 1999 , 833, 209-15	65
468	Ultrastructural localization of cellular prion protein (PrP _C) at the neuromuscular junction. 1999 , 55, 261-7	30

467	MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. 1999 , 6, 1-6	140
466	Cellular pathogenesis of Alzheimer's disease. 1999 , 53, 127-9	1
465	Neurohormonal Signaling Pathways and the Regulation of Alzheimer beta-Amyloid Precursor Metabolism. 1999 , 10, 273-279	32
464	Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. 1999 , 90, 1217-26	99
463	Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice. 1999 , 92, 1273-86	58
462	Basement membranes, microfibrils and beta amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings. 1999 , 29, 218-31	43
461	Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. 1999 , 20, 65-9	30
460	Biochemical assay for amyloid beta deposits to distinguish Alzheimer's disease from other dementias. 1999 , 280, 147-59	12
459	Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. 1999 , 38, 9373-8	192
458	Apolipoprotein Serum Amyloid A in Alzheimer's Disease. 1999 , 1, 155-167	33
457	Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. 1999 , 38, 4595-603	117
456	Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. 1999 , 149, 32-40	231
455	A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. 2000 , 11, 29-35	32
454	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. <i>Biochemical Journal</i> , 2000 , 348, 359	3.8 75
453	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. <i>Biochemical Journal</i> , 2000 , 348, 359-365	3.8 189
452	Reversible brain creatine deficiency in two sisters with normal blood creatine level. 2000 , 47, 511-513	121
451	Sonic hedgehog signal peptide mutation in a patient with holoprosencephaly. 2000 , 47, 514-516	13
450	Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. 2000 , 47, 517-520	55

449	Synphilin-1 is present in Lewy bodies in Parkinson's disease. 2000 , 47, 521-523	225
448	Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. 2000 , 47, 524-527	110
447	A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. 2000 , 47, 528-531	35
446	A novel congenital myopathy with apoptotic changes. 2000 , 47, 531-536	16
445	Novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease. 2000 , 47, 536-540	56
444	Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. 2000 , 47, 540-543	77
443	Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele. 2000 , 47, 544-549	26
442	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. 2000 , 47, 739-747	262
441	Physiopathologie des amyloses. 2000 , 67, 189-196	1
440	Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. 2000 , 6, 643-51	267
439	Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. 2000 , 903, 24-33	109
438	Identification of novel genes in late-onset Alzheimer's disease. 2000 , 35, 1343-52	165
437	Traumatic brain injury as a risk factor for Alzheimer's disease: a review. 2000 , 10, 115-29	172
436	The genetics of Alzheimer's disease. 2000 , 2, 158-64	46
435	Immunohistochemical detection of apolipoprotein E within prion-associated lesions in squirrel monkey brains. 2000 , 100, 365-70	13
434	Islet Amyloid Development in a Mouse Strain Lacking Endogenous Islet Amyloid Polypeptide (IAPP) but Expressing Human IAPP. <i>Molecular Medicine</i> , 2000 , 6, 998-1007	6.2 59
433	Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. 2000 , 57, 646-50	88
432	Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. 2000 , 11, 329-82	96

431	Apolipoprotein E and neuromuscular disease: a critical review of the literature. 2000 , 57, 1561-5		56
430	Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. 2000 , 43, 161-9		27
429	Antiproteases and cells in the pathogenesis of beta(2)-microglobulin amyloidosis: role of alpha(2)-macroglobulin and macrophages. 2000 , 86, 1-11		5
428	Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands. 2000 , 275, 1673-8		56
427	Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. 2000 , 7, 321-31		847
426	Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. 2000 , 97, 2892-7		714
425	Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. <i>American Journal of Human Genetics</i> , 2000 , 67, 1136-43	11	39
424	Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. <i>American Journal of Pathology</i> , 2000 , 157, 2003-10	5.8	100
423	Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. <i>American Journal of Pathology</i> , 2000 , 156, 951-64	5.8	197
422	Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. 2000 , 79, 1008-15		20
421	Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. 2000 , 101, 879-84		96
420	The cause of neuronal degeneration in Alzheimer's disease. 2000 , 60, 139-65		201
419	The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. 2000 , 21, 245-55		122
418	Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. 2000 , 21, 357-61		80
417	Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism. 2000 , 1502, 44-52		27
416	The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. 2000 , 1502, 85-94		69
415	Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. 2000 , 7, 153-65		30
414	Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. 2001 , 285, 903-8		47

413	A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. 2001 , 8, 890-9	462
412	Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (A β) and apoE/A β complexes on protein kinase C- α (PKC- α) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. 2001 , 38, 615-25	41
411	Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. 2001 , 39, 361-70	25
410	Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. 2001 , 39, 415-25	134
409	Apolipoprotein E and apolipoprotein E receptors modulate A β -induced glial neuroinflammatory responses. 2001 , 39, 427-34	102
408	Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. 2001 , 22, 931-6	67
407	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. 2001 , 22, 923-30	69
406	Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E. 2001 , 104, 223-34	35
405	Plasma factors controlling atrial natriuretic peptide (ANP) aggregation: role of lipoproteins. 2001 , 1536, 123-32	3
404	Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. 2001 , 1537, 179-203	216
403	Apolipoprotein E inhibits the depolymerization of beta 2-microglobulin-related amyloid fibrils at a neutral pH. 2001 , 40, 8499-507	66
402	A Genomic Search for Alzheimer's Disease Genes. 31-43	
401	The Natural History of Alzheimer's Disease: Minding the Gaps in Understanding the Mechanisms of Neurodegeneration. 2001 , 1-21	
400	Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. 2001 , 3, 23-30	74
399	Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. 2001 , 21, 1444-51	119
398	Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. 2001 , 21, 6026-35	62
397	Beta-VLDL protects against A β (1-42) and apoE toxicity in human SH-SY5Y neuroblastoma cells. 2001 , 12, 201-6	22
396	Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. 2001 , 60, 94-104	128

395	alpha(1)-antichymotrypsin polymorphism: a risk factor for hemorrhagic stroke in normotensive subjects. 2001 , 32, 2588-91	18
394	Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. 2001 , 32, 1181-4	68
393	The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. 2001 , 21, 8370-7	1210
392	Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. 2001 , 21, 299-315	19
391	Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. 2001 , 17, 147-55	107
390	Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. 2001 , 108, 231-46	54
389	Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target?. 2001 , 123, 47-57	69
388	Apolipoprotein E deposition and astrogliosis are associated with maturation of beta-amyloid plaques in betaAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease. 2001 , 900, 48-56	32
387	Significance of the variant and full-length forms of the very low density lipoprotein receptor in brain. 2001 , 922, 209-15	11
386	Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. 2001 , 31, 1120-31	137
385	Pathogenesis of beta2-microglobulin amyloidosis. 2001 , 51, 1-10	43
384	Vascular amyloid of unknown origin and senile transthyretin amyloid in the lung and gastrointestinal tract of old age: histological and immunohistochemical studies. 2001 , 51, 326-32	16
383	Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. 2001 , 5, 254-66	89
382	A study of apolipoproteins E and A-I in cutaneous amyloids. 2001 , 145, 422-7	9
381	Extension of A beta2M amyloid fibrils with recombinant human beta2-microglobulin. 2001 , 8, 30-40	26
380	Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. 2001 , 60, 342-9	85
379	Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. 2001 , 98, 8838-43	307
378	Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. 2001 , 10, 2525-37	39

377	Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. 2002 , 277, 50380-5		154
376	Conformation of beta 2-microglobulin amyloid fibrils analyzed by reduction of the disulfide bond. 2002 , 277, 21554-60		58
375	Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. 2002 , 61, 254-67		102
374	The genetics of Alzheimer's disease. 2002 , 8, 20-23		2
373	The challenge of inhibiting Abeta polymerization. 2002 , 9, 1121-33		43
372	Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. 2002 , 41, 8203-11		19
371	Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. 2002 , 10, 187-200		6
370	LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. 2002 , 104, 38-46		67
369	Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2002 , 23, 1205-14		64
368	Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. 2002 , 23, 1051-72		115
367	Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. 2002 , 23, 1009-16		31
366	Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. 2002 , 114, 1103-14		30
365	Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2002 , 331, 171-4	3-3	40
364	Human Cerebrospinal Fluid Apolipoprotein E Isoforms are Apparently Inefficient at Complexing with Synthetic Alzheimer's Amyloid- β Peptide (A β 40) in vitro. <i>Molecular Medicine</i> , 2002 , 8, 376-381	6.2	5
363	Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. 2002 , 22, 10539-48		165
362	Effects of Free Fatty Acid on Polymerization of Islet Amyloid Polypeptide (IAPP) In Vitro and on Amyloid Fibril Formation in Cultivated Islets of Transgenic Mice Overexpressing Human IAPP. <i>Molecular Medicine</i> , 2002 , 8, 863-868	6.2	28
361	Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. 2002 , 52, 40-5		41
360	Immunization for Alzheimer's disease. 2002 , 56, 135-142		8

359	Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Strüssler-Scheinker syndrome P102L mutation complicated with dementia. 2002 , 104, 342-50	37
358	Apolipoprotein E4 is associated with primary localized cutaneous amyloidosis. 2002 , 119, 532-3	6
357	Monoclonal antibodies against the human metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's disease brain. 1996 , 66, 2011-8	13
356	Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. 1997 , 68, 721-5	86
355	Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. 1997 , 68, 760-9	60
354	The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. 1997 , 69, 1177-84	94
353	Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. 1997 , 69, 1995-2004	121
352	High-density lipoprotein aggregated by oxidation induces degeneration of neuronal cells. 1997 , 69, 2102-14	21
351	Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. 1998 , 70, 210-5	111
350	Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. 1998 , 71, 1626-34	47
349	Genetic variation in memory functioning. 2002 , 26, 841-8	32
348	Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?. 2003 , 28, 585-92	70
347	Snake coiled fibres in rat soleus muscle in chloroquine induced myopathy share immunohistochemical characteristics with amyloid depositions in Alzheimer's disease brain tissue. 1997 , 78, 1-8	2
346	Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. 2003 , 122, 305-15	153
345	Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. 2003 , 310, 303-11	71
344	Differential metabolism of ApoE isoforms in plasma and CSF. 2003 , 183, 4-6	14
343	TGFbeta1 enhances formation of cellular Abeta/apoE deposits in vascular myocytes. 2003 , 24, 355-64	17
342	Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes. 2003 , 60, 105-10	13

341	Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glia cell cultures. 2003 , 116, 437-45	64
340	Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. 2003 , 100, 10966-71	268
339	Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. 2003 , 278, 34874-81	117
338	Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. 2003 , 278, 8043-51	94
337	Splenic ellipsoids: an early target for deposition of AA amyloid induced in mink. 2003 , 10, 240-9	3
336	Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. 2003 , 17, 259-66	37
335	Apolipoprotein E influences amyloid-beta clearance from the murine periphery. 2003 , 5, 1-8	57
334	Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. 2004 , 6, 509-14	12
333	Proteomic Applications for Molecular Assessment of Alzheimer's Disease. 2004 , 355-370	
332	Brain cholesterol: long secret life behind a barrier. 2004 , 24, 806-15	675
331	Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. 2004 , 24, 2527-34	289
330	Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. 2004 , 89, 3629-43	427
329	Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. 2004 , 279, 44795-801	100
328	Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer. 2004 , 279, 25511-6	58
327	Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. 2004 , 279, 3862-8	90
326	Non-fibrillar components of amyloid deposits mediate the self-association and tangling of amyloid fibrils. 2004 , 279, 21038-45	28
325	APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. 2004 , 62, 2116-8	115
324	Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. 2004 , 90, 1132-43	79

323	Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. 2004 , 23, 151-5		12
322	Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. 2004 , 23, 189-204		144
321	ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. 2004 , 23, 235-46		72
320	Links between the pathology of Alzheimer's disease and vascular dementia. 2004 , 29, 1257-66		80
319	Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?. 2004 , 47, 157-69		163
318	The role of apolipoprotein E in lipid metabolism in the central nervous system. 2004 , 61, 1896-906		60
317	Clinical manifestations of cerebral amyloid angiopathy-related inflammation. 2004 , 55, 250-6		290
316	[BIG-H3 protein: mutation of codon 124 and corneal amyloidosis]. 2004 , 27, 510-22		
315	Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. 2004 , 25, 1153-67		64
314	Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. 2004 , 124, 725-33		86
313	A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. <i>American Journal of Pathology</i> , 2004 , 165, 937-48	5.8	122
312	ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. 2004 , 41, 193-202		355
311	Vascular smooth muscle actin is reduced in Alzheimer disease brain: a quantitative analysis. 2004 , 63, 735-41		30
310	Insertion of the amyloid precursor protein into lipid monolayers: effects of cholesterol and apolipoprotein E. <i>Biochemical Journal</i> , 2004 , 382, 987-94	3.8	22
309	The Amyloid I-Protein. 384-491		2
308	Kinetic analysis of the polymerization and depolymerization of beta(2)-microglobulin-related amyloid fibrils in vitro. 2005 , 1753, 34-43		23
307	Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. 2005 , 137, 52-61		39
306	Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex. 2005 , 20, 574-82		42

305	Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interaction. 2005 , 80, 877-86	21
304	Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats. 2005 , 82, 103-14	40
303	Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. 2005 , 110, 459-71	42
302	Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. 2005 , 7, 231-42	31
301	Problems associated with biological markers of Alzheimer's disease. 2005 , 30, 1501-10	29
300	Lipid Modulators of Protein Misfolding and Aggregation. 111-129	
299	Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. 2005 , 53, 237-42	12
298	F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. 2005 , 25, 9259-68	99
297	The interaction of amyloid-beta with ApoE. 2005 , 38, 255-72	47
296	Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. 2005 , 2, 65-77	131
295	Serum amyloid A in geese; cloning and expression of recombinant protein. 2005 , 12, 109-14	5
294	Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. 2005 , 280, 43236-42	243
293	Alzheimer's Disease. 2005 ,	7
292	Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils. 2005 , 12, 15-25	33
291	Effects of apolipoprotein E genotypes on the development of exfoliation syndrome. 2005 , 80, 871-5	26
290	Transgenic models of Alzheimer's disease: learning from animals. 2005 , 2, 423-37	154
289	Pathophysiology of Alzheimer's disease. 2005 , 15, 727-53, ix	52
288	Alzheimer: 100 Years and Beyond. 2006 ,	5

287	Protein Design. 2006 ,		
286	Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. 2006 , 8, 2021-37		192
285	Apolipoprotein E and Alzheimer disease. 2006 , 66, S79-85		83
284	Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. 2006 , 361, 932-44		68
283	Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. 2006 , 48, 718-28		71
282	Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. <i>Neuroscience Letters</i> , 2006 , 408, 46-50	3-3	34
281	Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease. 2006 , 143, 689-701		57
280	Apolipoprotein-E modulates the cytotoxic effect of β amyloid on rat brain endothelium in an isoform-dependent specific manner. 2006 , 17, 821		1
279	Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons. <i>Molecular Neurodegeneration</i> , 2006 , 1, 18	19	27
278	Apolipoprotein E4 suppresses delayed-rectifier potassium channels in membrane patches excised from hippocampal neurons. 2006 , 59, 82-91		4
277	Sporadic and familial cerebral amyloid angiopathies. 2002 , 12, 343-57		137
276	Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. 2005 , 15, 72-7		43
275	Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology. 2006 , 185, 8-14		103
274	Comprehensive theory of Alzheimer's disease. The effects of cholesterol on membrane receptor trafficking. 2000 , 924, 104-11		17
273	Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. 2006 , 32, 492-504		24
272	Role of ApoE in conformation-prone diseases and atherosclerosis. 2006 , 71, 707-12		2
271	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. 2006 , 11, 721-36		274
270	Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. 2006 , 111, 139-49		102

269	Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. 2006 , 129, 3020-34	85
268	Protein misfolding disorders and rational design of antimisfolding agents. 2006 , 340, 277-93	7
267	Apolipoproteins in Different Amyloidoses. 2006 , 101-122	2
266	Immunotherapy for conformational diseases. 2006 , 12, 2569-85	20
265	Outcome of traumatic brain injury after three decades--relationship to ApoE genotype. 2006 , 23, 1600-8	46
264	Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. 2006 , 26, 4985-94	301
263	Protein Misfolding, Aggregation, and Conformational Diseases. 2007 ,	13
262	Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. 2007 , 104, 6412-7	118
261	Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E. 2007 , 282, 35831-41	22
260	Disease modifying approaches for Alzheimer's pathology. 2007 , 13, 1943-54	37
259	Normal tension glaucoma is not associated with the interleukin -1alpha (-889) genetic polymorphism. 2007 , 16, 230-3	10
258	Novel strategies for Alzheimer's disease treatment. 2007 , 7, 1853-67	22
257	Structural variation manipulates the differential oxidative susceptibility and conformational stability of apolipoprotein E isoforms. 2007 , 68, 363-74	3
256	Therapeutic approaches for prion and Alzheimer's diseases. <i>FEBS Journal</i> , 2007 , 274, 3784-98	5.7 32
255	Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. 2007 , 35, 203-16	92
254	Sulfatides facilitate apolipoprotein E-mediated amyloid-beta peptide clearance through an endocytotic pathway. 2008 , 106, 1275-86	20
253	Apolipoprotein E type epsilon4 allele, heritability and age at onset in twins with Alzheimer disease and vascular dementia. 1997 , 52, 408-13	18
252	A study of apolipoproteins E and AII in cutaneous amyloids. 2008 , 145, 422-427	

251	Characterization of Proteoglycans and Glycosaminoglycans in Splenic AA Amyloid Induced in Mink. 2008 , 52, 576-583	
250	Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. 2008 , 9 Suppl 2, S5	33
249	The metal loading ability of beta-amyloid N-terminus: a combined potentiometric and spectroscopic study of copper(II) complexes with beta-amyloid(1-16), its short or mutated peptide fragments, and its polyethylene glycol (PEG)-ylated analogue. 2008 , 47, 9669-83	84
248	Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition. 2008 , 17, 303-11	20
247	Prevention and promotion effects of apolipoprotein E4 on amylin aggregation. 2008 , 368, 414-8	9
246	Sialic acid moiety of apolipoprotein E3 at Thr(194) affects its interaction with beta-amyloid(1-42) peptides. 2008 , 388, 123-9	13
245	Analysis of the structural and dynamic properties of human N-terminal domain of apolipoprotein E by molecular dynamics simulations. 2008 , 112, 8730-6	3
244	New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential therapeutics. 2008 , 7, 270-7	39
243	Neurohormonal signalling pathways and the regulation of Alzheimer beta-amyloid metabolism. 2000 , 230, 239-51; discussion 251-3	1
242	Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. 1996 , 93, 133-7	23
241	Amyloid beta induces cellular relocalization and production of agrin and glypican-1. 2009 , 1260, 38-46	13
240	Beyond proof of principle: new genes for Alzheimer's disease through collaboration. 2009 , 8, 977-9	3
239	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. 2009 , 118, 103-13	660
238	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. 2009 , 111, 1275-308	165
237	A novel technique for simultaneous bilateral brain infusions in a mouse model of neurodegenerative disease. 2009 , 184, 320-6	4
236	The role of apolipoprotein E in Alzheimer's disease. 2009 , 63, 287-303	1032
235	Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. 2009 , 284, 158-62	28
234	Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. 2009 , 284, 6027-31	98

233	Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid- β clearance in Alzheimer's disease. 2010 , 7, 578-90	24
232	Apolipoprotein E genotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. 2010 , 19, 561-5	18
231	Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. 2010 , 21, 337-45	62
230	Do amyloid β -associated factors co-deposit with A β in mouse models for Alzheimer's disease?. 2010 , 22, 345-55	13
229	Alzheimer disease. 2010 , 56, 484-546	290
228	Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. 2010 , 67, 581-600	43
227	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. 2010 , 214, 201-18	35
226	The role of microglia in amyloid clearance from the AD brain. 2010 , 117, 949-60	393
225	The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. 2010 , 41, 97-106	28
224	Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. 2010 , 23, 1085-95	20
223	Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro. 2010 , 44, 305-13	21
222	Strategies for the inhibition of protein aggregation in human diseases. 2010 , 11, 1018-35	100
221	Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. 2010 , 30, 13707-17	208
220	Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. 2010 , 219683	22
219	Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. 2010 , 16, 287-94	132
218	Murine models of Alzheimer's disease and their use in developing immunotherapies. 2010 , 1802, 847-59	55
217	Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. 2010 , 31, 1503-15	138
216	Apolipoproteins in the brain: implications for neurological and psychiatric disorders. 2010 , 51, 555-573	111

215	Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease. <i>American Journal of Pathology</i> , 2011 , 178, 2286-98	5.8	30
214	Apolipoprotein E: from lipid transport to neurobiology. 2011 , 50, 62-74		194
213	Blocking the apolipoprotein E/amyloid- β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. 2011 , 24, 269-85		40
212	Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?. <i>Molecular Neurodegeneration</i> , 2011 , 6, 79	19	69
211	Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models. 2011 , 39, 924-32		28
210	A differential association of Apolipoprotein E isoforms with the amyloid- β oligomer in solution. 2011 , 79, 402-16		37
209	The use of mass spectrometry to study amyloid- β peptides. 2011 , 30, 347-65		37
208	Genetic mouse models of neurodegenerative diseases. 2011 , 100, 419-82		33
207	High ability of apolipoprotein E4 to stabilize amyloid- β peptide oligomers, the pathological entities responsible for Alzheimer's disease. 2011 , 25, 1585-95		67
206	Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. 2012 , 32, 13125-36		85
205	Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia. 2012 , 303, R19-29		37
204	Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. 2012 , 2, a006312		497
203	Apolipoprotein E promotes β amyloid trafficking and degradation by modulating microglial cholesterol levels. 2012 , 287, 2032-44		109
202	Reducing human apolipoprotein E levels attenuates age-dependent A β accumulation in mutant human amyloid precursor protein transgenic mice. 2012 , 32, 4803-11		115
201	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A β amyloidosis. 2012 , 209, 2149-56		92
200	Neurovascular defects and faulty amyloid- β vascular clearance in Alzheimer's disease. 2013 , 33 Suppl 1, S87-100		83
199	Roles of extracellular chaperones in amyloidosis. 2012 , 421, 499-516		41
198	Search for amyloid-binding proteins by affinity chromatography. 2012 , 849, 213-23		27

197	GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. 2011 , 23, 1-11	114
196	Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. 2012 , 2012, 489428	55
195	Ischemia signalling to Alzheimer-related genes. 2012 , 50, 322-9	18
194	APOE genotype alters glial activation and loss of synaptic markers in mice. 2012 , 60, 559-69	131
193	Untangling the role of tau in Alzheimer's disease: A unifying hypothesis. 2013 , 4,	8
192	Molecular links between Alzheimer's disease and diabetes mellitus. 2013 , 250, 140-50	132
191	Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. 2013 , 5, 212ra161	108
190	The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE e2. 2013 , 37, 2878-86	124
189	Immunization targeting a minor plaque constituent clears β amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. 2013 , 34, 137-45	32
188	Levels of soluble apolipoprotein E/amyloid- β complex are reduced and oligomeric A β increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. 2013 , 288, 5914-26	108
187	Sporadic Alzheimer's disease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer's disease genes. 2013 , 48, 500-15	82
186	Copper(II) and zinc(II) dependent effects on A β 2 aggregation: a CD, Th-T and SFM study. 2013 , 37, 1206	10
185	Inhibiting Peptide and Protein Self-Aggregation: What Can Simulations Tell Us?. 2013 , 401-437	
184	Binding of apolipoprotein E inhibits the oligomer growth of amyloid- β peptide in solution as determined by fluorescence cross-correlation spectroscopy. 2013 , 288, 11628-35	32
183	Hormonal modulators of glial ABCA1 and apoE levels. 2013 , 54, 3139-50	10
182	Age and apolipoprotein E β effects on neural correlates of odor memory. 2013 , 127, 339-49	11
181	ApoE influences amyloid- β clearance despite minimal apoE/A β association in physiological conditions. 2013 , 110, E1807-16	336
180	Proteomic analysis of highly prevalent amyloid A amyloidosis endemic to endangered island foxes. 2014 , 9, e113765	13

179	Apolipoprotein E4 impairs in vivo hippocampal long-term synaptic plasticity by reducing the phosphorylation of CaMKII β and CREB. 2014 , 41, 1165-76		18
178	Imaging the Morphology and Structure of Apolipoprotein Amyloid Fibrils. 2014 , 247-254		
177	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. 2014 , 85, 266-73		40
176	Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE ^{-/-} mice brains. 2015 , 43, 67-80		98
175	APOE gene polymorphisms and susceptibility to Creutzfeldt-Jakob disease. 2014 , 21, 390-4		10
174	Soluble apoE/A β complex: mechanism and therapeutic target for APOE4-induced AD risk. <i>Molecular Neurodegeneration</i> , 2014 , 9, 2	19	87
173	Genetics of Alzheimer's disease. 2014 , 87, 245-94		134
172	Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. 2014 , 72 Pt A, 3-12		311
171	The binding of apolipoprotein E to oligomers and fibrils of amyloid- β alters the kinetics of amyloid aggregation. 2014 , 53, 6323-31		75
170	Genetics of cognition in epilepsy. 2014 , 41, 297-306		15
169	Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 70	7.3	31
168	Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. 2015 , 16, 69		44
167	Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity. 2015 , 134, 1116-28		11
166	Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. 2015 , 7, 136		117
165	Role of apolipoprotein E in neurodegenerative diseases. 2015 , 11, 1723-37		101
164	Label-free detection of ApoE4-mediated β amyloid aggregation on single nanoparticle uncovering Alzheimer's disease. 2015 , 72, 197-204		43
163	Stabilization of intracellular trafficking and metabolism of amyloid β protein precursor and Alcadein β by apolipoprotein E. 2015 , 589, 2394-400		3
162	Current and future implications of basic and translational research on amyloid- β peptide production and removal pathways. 2015 , 66, 3-11		50

161	High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism. 2015 , 10, 69-81	1
160	APOE ϵ moderates abnormal CSF- β 42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. 2015 , 15, 51	40
159	The role of apolipoprotein E epsilon (ϵ 4) allele on outcome following traumatic brain injury: A systematic review. 2015 , 29, 1018-31	57
158	New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits. 2016 , 73, 638-40	2
157	Quercetin stabilizes apolipoprotein E and reduces brain A β levels in amyloid model mice. 2016 , 108, 179-92	35
156	Copper(II) coordination properties of the A β (1-6)2 peptidomimetic: experimental evidence of intermolecular macrochelate complex species in the A β dimer. 2016 , 40, 10274-10284	5
155	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. 2017 , 28, 60-67	84
154	Blood-Brain Barrier Transport of Alzheimer's Amyloid β Peptide. 2016 , 251-270	4
153	Alzheimer's Disease Therapeutics Targeting Apolipoprotein E. 2016 , 271-303	
152	TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. 2016 , 17, 201-7	220
151	Brain ischemia with Alzheimer phenotype dysregulates Alzheimer's disease-related proteins. 2016 , 68, 582-91	17
150	Evidence of increased brain amyloid in severe TBI survivors at 1, 12, and 24 months after injury: report of 2 cases. 2016 , 124, 1646-53	16
149	Modulation on brain gray matter activity and white matter integrity by APOE ϵ risk gene in cognitively intact elderly: A multimodal neuroimaging study. 2017 , 322, 100-109	9
148	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- β and other amyloidogenic proteins. 2017 , 58, 824-836	106
147	Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. 2017 , 133, 933-954	101
146	Anti-fibrillogenic and fibril destabilizing effects of metal ions on cystatin fibrils. 2017 , 57, 105-116	4
145	Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_A β 7-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline. 2017 , 7, 8009	31
144	Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps. 2017 , 39, 1700062	7

143	The blood-brain barrier in Alzheimer's disease. 2017 , 107, 41-56		286
142	Dysregulation of Alzheimer's disease-related genes and proteins following cardiac arrest. 2017 , 55, 283-288		11
141	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease. 2018 , 64, S299-S312		18
140	Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. 2018 , 38, 261-324		41
139	Microglia in Alzheimer's disease. 2018 , 217, 459-472		581
138	Deletion of plasma increases microglial phagocytosis and reduces cerebral amyloid- β deposition in the J20 mouse model of Alzheimer's disease. 2018 , 9, 19688-19703		9
137	A hybrid computational approach for efficient Alzheimer's disease classification based on heterogeneous data. 2018 , 8, 9774		29
136	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018 , 97, 625-648	1.2	6
135	Alternative hypotheses related to Alzheimer's disease. 2018 , 119, 210-216		10
134	Prospective Associations between Single Foods, Alzheimer's Dementia and Memory Decline in the Elderly. 2018 , 10,		35
133	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. 2018 , 18, 759-772		222
132	APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis. 2019 , 56, 2450-2465		88
131	High-affinity multivalent interactions between apolipoprotein E and the oligomers of amyloid- β <i>FEBS Journal</i> , 2019 , 286, 4737-4753	5.7	14
130	Targeting apolipoprotein E for treating Alzheimer's disease. <i>Neuroscience Letters</i> , 2019 , 709, 134366	3.3	1
129	Lack of hepatic apoE does not influence early A β deposition: observations from a new APOE knock-in model. <i>Molecular Neurodegeneration</i> , 2019 , 14, 37	19	26
128	Future horizons in Alzheimer's disease research. 2019 , 168, 223-241		10
127	Higher Level of Mismatch in APOE ϵ Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. 2019 , 11, 1759091419845524		6
126	Hidden Aggregation Hot-Spots on Human Apolipoprotein E: A Structural Study. 2019 , 20,		4

125	A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. 2019 , 101, 820-838		160
124	heterozygosity attenuates β -related amyloid burden in preclinical AD. 2019 , 92, e1878-e1889		29
123	Comparison between amyloid-PET and CSF amyloid- β biomarkers in a clinical cohort with memory deficits. 2019 , 492, 62-68		11
122	Electrochemical Detection of Isoform-Specific Interaction between Apolipoprotein E and Amyloid- β 2019 , 6, 834-840		2
121	Apolipoprotein E impairs amyloid- β fibril elongation and maturation. <i>FEBS Journal</i> , 2020 , 287, 1208-1219	5-7	4
120	APOE in the normal brain. 2020 , 136, 104724		39
119	Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer's Disease. 2020 , 20,		16
118	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1. <i>Molecular Neurodegeneration</i> , 2020 , 15, 53	19	18
117	Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. 2020 , 10,		13
116	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of A β 2 and Its Protein Aggregates. 2020 , 57, 3803-3813		19
115	APOE-amyloid interaction: Therapeutic targets. 2020 , 138, 104784		27
114	Apolipoprotein E Interferes with IAPP Aggregation and Protects Pericytes from IAPP-Induced Toxicity. <i>Biomolecules</i> , 2020 , 10,	5-9	7
113	Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study. 2021 , 17, 446-456		5
112	Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. 2021 , 109, 205-221		39
111	Quantitative interrogation of protein co-aggregation using multi-color fluorogenic protein aggregation sensors. 2021 , 12, 8468-8476		7
110	Pericytes and the Neurovascular Unit: The Critical Nexus of Alzheimer Disease Pathogenesis?. 2021 , 000, 000-000		
109	The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer's Disease: Exploring Interactions With Sex. 2021 , 15, 633576		0
108	Mechanisms of Transthyretin Inhibition of IAPP Amyloid Formation. <i>Biomolecules</i> , 2021 , 11,	5-9	2

107	Complement 9 in amyloid deposits. 2021 , 28, 199-208	2
106	Development of liquid crystal biosensor for the detection of amyloid beta-42 levels associated with Alzheimer's disease. 2021 , 132, 88-94	3
105	Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid- β 2021 , 1866, 158980	3
104	Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. 2021 , 13, 718426	3
103	Apolipoprotein E and amyloidogenesis. 1996 , 199, 132-41; discussion 141-5	3
102	Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer's Disease. 2007 , 179-198	5
101	Pancreatic Islet Amyloid and Diabetes. 2007 , 199-216	3
100	Regulation of alzheimer beta-amyloid precursor trafficking and metabolism. 2001 , 487, 85-100	10
99	Roles of CNS Macrophages in Neurodegeneration. 1998 , 1-59	9
98	Alzheimer's Disease and Hemorrhagic Stroke: Their Relationship to A β Amyloid Deposition. 1995 , 37-48	3
97	Chaperoning Amyloid in Alzheimer's Disease: The Art of Avoiding Sticky Situations?. 1996 , 151-160	1
96	Apolipoprotein E Oxidation and Functional Consequences. 1996 , 161-169	2
95	Role of Apolipoprotein E in Alzheimer's Disease: Clues from its Structure. 1996 , 11-19	1
94	Pattern of Apolipoprotein E Immunoreactivity During Brain Aging. 1996 , 29-48	3
93	Very Low Density Lipoprotein Receptor and Alzheimer's Disease. 1996 , 74-96	3
92	Amyloid in Alzheimer's Disease and Animal Models. 1994 , 156-168	1
91	Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?. 1996 , 47, 259-66	9
90	Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. 1998 , 54, 167-74	30

89	Oxidative Modification of Apolipoprotein E3 and Its Biological Significance. 1998 , 597-602		1
88	Vascular Transport of Alzheimer's Amyloid β Peptides and Apolipoproteins. 2000 , 325-346		1
87	Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer's Amyloid deposition. 1994 , 88, 413		8
86	Alzheimer's Disease. 2000 , 1228-1238		2
85	Isoform-specific binding of apolipoprotein E to beta-amyloid.. 1994 , 269, 23403-23406		367
84	Physical Interaction of ApoE with Amyloid Precursor Protein Independent of the Amyloid A β Region in Vitro. 1998 , 273, 13892-13897		28
83	Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. 2001 , 42, 976-987		31
82	beta-amyloid (A β) ₄₂ (₄₃), abeta ₄₂ , abeta ₄₀ and apoE immunostaining of plaques in fatal head injury. 2000 , 26, 124-32		64
81	Characterization of proteoglycans and glycosaminoglycans in splenic AA amyloid induced in mink. 2000 , 52, 576-83		9
80	Identification of MEFV-Independent Modifying Genetic Factors for Familial Mediterranean Fever. <i>American Journal of Human Genetics</i> , 2000 , 67, 1136-1143	11	188
79	ApoE-epsilon 4 allele and susceptibility to drug-induced memory impairment in the elderly. 1998 , 18, 179-81		7
78	Beta-amyloid-induced coronary artery vasoactivity and endothelial damage. 1997 , 30, 517-22		15
77	Apolipoprotein E interacts with amyloid- β oligomers via positively cooperative multivalent binding.		2
76	Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. 1995 , 26, 743-8		59
75	Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. 1999 , 103, R15-R21		253
74	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. 2018 , 128, 2144-2155		72
73	Using Proteomics to Understand Alzheimer's Disease Pathogenesis. 37-51		3
72	Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role?. 2017 , 14, 208-220		39

71	Apolipoprotein E and cholesterol in aging and disease in the brain. 2008 , 3, 505-530	110
70	Opposing Roles of apolipoprotein E in aging and neurodegeneration. 2019 , 2,	13
69	The development and physiological and pathophysiological functions of resident macrophages and glial cells. 2021 , 151, 1-47	0
68	Chemical Analysis of Amyloid β Protein in CAA. 2000 , 157-177	1
67	Genetically Engineered Models of Human Age-Related Neurodegenerative Diseases. 2001 , 387-406	1
66	Interactions of α -macroglobulin and amyloid β peptide. 2001 , 145-154	1
65	Neurohormonal Signalling Pathways and the Regulation of Alzheimer β Amyloid Metabolism Integrating Basic and Clinical Observations for Developing Successful Strategies to Delay, Retard or Prevent Cerebral Amyloidosis in Alzheimer's Disease. 2002 , 409-422	
64	Amyloid Precursor Protein.	
63	Alzheimer's Disease: Search for Therapeutics. 2003 , 743-777	1
62	Alzheimer's Disease and Vascular Dementia. 2004 , 103-130	
61	Molecular Genetics of Alzheimer's Disease. 2009 , 229-276	0
60	Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. 1994 , 44, 29-45	13
59	Processing of Alzheimer A β Amyloid Precursor Protein: Cell Biology, Regulation, and Role in Alzheimer's Disease. 1994 , 100-120	
58	Phenotypes and Genotypes of Apolipoprotein E in Japanese Patients with Late-Onset Sporadic Alzheimer's Disease, Vascular Dementia, Down's Syndrome or Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 1995 , 189-196	
57	Apolipoprotein E and Alzheimer's Disease. 1995 , 385-391	
56	Apolipoprotein E and Apolipoprotein E Receptors in the Central Nervous System: Relationship with Alzheimer's Disease. 1996 , 97-102	
55	Interactions of Apolipoprotein E with Microtubule-Associated Proteins. 1996 , 145-150	
54	Apolipoprotein E Uptake is Increased by Beta-Amyloid Peptides and Reduced by Blockade of the LDL Receptor. 1996 , 103-108	

53	Pathology, Neurobiology, and Animal Models of Alzheimer's Disease. 1996 ,		
52	Potential Biological Mechanisms of ApoE in Alzheimer's Disease. 1997 , 21-37		
51	Pathological Changes in the Elderly Human Brain. 1997 , 5-114		
50	Etiological Considerations. 1997 , 153-185		
49	Peptides Inhibitor of Amyloidogenesis in Alzheimer's Disease. 1997 , 91-97		
48	Differential Susceptibility of Human Apolipoprotein E Isoforms to Oxidation and Consequences on their Interaction with Phospholipids. <i>Advances in Behavioral Biology</i> , 1998 , 31-38		
47	Role of Apolipoprotein E in Alzheimer's Disease. 1998 , 179-209		3
46	HB-GAM, a Novel Amyloid Associated Protein, is Present in Prion Related Disorders and other Cerebral Amyloidoses. <i>Advances in Behavioral Biology</i> , 1998 , 121-131		
45	Model of Genetic Susceptibility to Late-Onset Alzheimer's Disease: Mice Transgenic for Human Apolipoprotein E Alleles. 1999 , 215-243		
44	Alzheimer's Disease and Genetically Engineered Animal Models. 1999 , 187-214		
43	Senile plaques in Alzheimer's disease arise from Cathepsin D and A β -enriched proteinaceous mixtures out of hemolysis and vascular degeneration.		0
42	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor complex are responsible for the cellular uptake of A β 2 and its protein aggregates.		
41	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. <i>Biochemical Journal</i> , 2000 , 348 Pt 2, 359-65	3.8	104
40	Amyloid A protein amyloidosis induced in apolipoprotein-E-deficient mice. <i>American Journal of Pathology</i> , 1997 , 151, 911-7	5.8	22
39	Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. <i>American Journal of Pathology</i> , 1998 , 152, 889-95	5.8	37
38	Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. <i>American Journal of Pathology</i> , 1998 , 152, 1387-95	5.8	38
37	The pathogenesis of amyloidosis: understanding general principles. <i>American Journal of Pathology</i> , 1998 , 152, 1125-7	5.8	28
36	Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. <i>American Journal of Pathology</i> , 1996 , 148, 2083-95	5.8	243

35	The Golgi apparatus and the pathogenesis of Alzheimer's disease. <i>American Journal of Pathology</i> , 1996 , 148, 355-60	5.8	15
34	Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). <i>American Journal of Pathology</i> , 1996 , 148, 361-6	5.8	67
33	Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. <i>American Journal of Pathology</i> , 1995 , 147, 238-44	5.8	85
32	Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. <i>American Journal of Pathology</i> , 1994 , 145, 1030-5	5.8	329
31	Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys. <i>American Journal of Pathology</i> , 1994 , 144, 1183-7	5.8	51
30	Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. <i>American Journal of Pathology</i> , 1994 , 145, 1472-84	5.8	83
29	Potential role of apolipoprotein-E in fibrillogenesis. <i>American Journal of Pathology</i> , 1994 , 145, 526-30	5.8	89
28	Apolipoprotein E: risk factor for Alzheimer disease. <i>American Journal of Human Genetics</i> , 1994 , 54, 643-9	11	181
27	The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer disease. <i>American Journal of Human Genetics</i> , 1994 , 54, 631-42	11	66
26	Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. <i>Molecular Medicine</i> , 1995 , 1, 542-53	6.2	6
25	Investigation of the association between interleukin-1beta polymorphism and normal tension glaucoma. <i>Molecular Vision</i> , 2007 , 13, 719-23	2.3	14
24	CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE. 2010 , 61, S111-S124		15
23	N6-methyladenine-modified DNA was decreased in Alzheimer's disease patients.. <i>World Journal of Clinical Cases</i> , 2022 , 10, 448-457	1.6	1
22	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A β accumulation and plaque-related pathology in a mouse model of amyloidosis.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 13	19	2
21	Antibodies gone bad - The molecular mechanism of light chain amyloidosis.. <i>FEBS Journal</i> , 2022 ,	5.7	1
20	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018 , 97, 625-648	1.2	1
19	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 20406223221081605	4.9	1
18	APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.. <i>Seminars in Immunology</i> , 2022 , 101594	10.7	5

17	Endogenous Human Proteins Interfering with Amyloid Formation.. <i>Biomolecules</i> , 2022 , 12,	5.9	1
16	In Silico Analysis of the Antagonist Effect of Enoxaparin on the ApoE4-Amyloid-Beta (A) Complex at Different pH Conditions.. <i>Biomolecules</i> , 2022 , 12,	5.9	1
15	The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 53	7.3	1
14	^1H , ^{15}N and ^{13}C chemical shift assignments of the N-terminal domain of the two isoforms of the human apolipoprotein E.. <i>Biomolecular NMR Assignments</i> , 2022 , 1	0.7	
13	ApoE: A Risk Factor for Dementia. 2022 , 3-29		0
12	Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect. 2022 , 23, 8384		1
11	Progress of advanced nanomaterials in diagnosis of neurodegenerative diseases. 2022 , 217, 114717		0
10	Molecular Mechanisms Underlying the Role of HSPB8 in Neurodegeneration. 2022 , 197-218		0
9	SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF.		1
8	Building in vitro models of the brain to understand the role of APOE in Alzheimer's disease. 2022 , 5, e202201542		
7	APOE ϵ genotype, amyloid- β and sex interact to predict tau in regions of high APOE mRNA expression. 2022 , 14,		0
6	Lack of ApoE inhibits ADan amyloidosis in a mouse model of familial Danish dementia. 2023 , 299, 102751		0
5	10q26 The enigma in age-related macular degeneration. 2022 , 101154		0
4	Extracellular Chaperone Networks and the Export of J-Domain Proteins. 2022 , 102840		0
3	TREATMENT DEVELOPMENT STRATEGIES FOR ALZHEIMER'S DISEASE. 1995 , 30, 147s-162s		0
2	Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds.		0
1	Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy. 2023 , 18,		0